Physician profile
Haroon Rashid
NPI 1073578274
$3,468.65
in general payments reported to CMS, 2019-2025
28 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $552 · 2021: $456 · 2022: $1,032 · 2023: $301 · 2024: $460 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $603.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $421.91 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $332.99 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $283.23 | 2020-2025 | |
| Viiv Healthcare Company | $197.95 | 2024-2025 | Apretude |
| Merck Sharp & Dohme LLC | $191.09 | 2020-2023 | Steglatro, Belsomra, Verquvo |
| Lilly USA, LLC | $156.16 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $144.61 | 2020-2022 | |
| Amgen INC. | $138.50 | 2019-2023 | Repatha, Otezla |
| Gilead Sciences, INC. | $115.55 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.73 | 2019 | |
| Abbvie INC. | $96.49 | 2022-2025 | |
| Novo Nordisk INC | $90.45 | 2019-2022 | |
| Biosense Webster, INC. | $84.30 | 2020 | |
| Eisai INC. | $66.83 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $53.77 | 2020-2021 | |
| Astellas Pharma US INC | $50.43 | 2021-2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $48.53 | 2023 | Seglentis |
| Biohaven Pharmaceuticals, INC. | $47.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.05 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.90 | 2022 | |
| Exact Sciences Corporation | $26.01 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $23.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.28 | 2019 | |
| Medtronic, INC. | $20.40 | 2025 | Inceptiv |
| Sunovion Pharmaceuticals INC. | $18.45 | 2019 | |
| Watermark Medical, INC. | $17.60 | 2024 | |
| Phadia US INC. | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.